Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1294

Sort by

Sort Order Select

Journal Articles

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Blood (2025) 146 (7): 874–886.

https://doi.org/10.1182/blood.2024027170

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Blood (2025) 145 (18): 1987–2001.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2025) 145 (11): 1126–1135.

https://doi.org/10.1182/blood.2024025464

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Blood (2024) 144 (23): 2402–2416.

https://doi.org/10.1182/blood.2024025023

Published: 2024

Includes: Supplemental data

Journal Articles

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Arjun S. Peddireddy, Panayiotis Kontoyiannis, Koji Sasaki, Kelly S. Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney D. DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia

Blood (2024) 144 (Supplement 1): 6704.

https://doi.org/10.1182/blood-2024-202540

Published: 2024

Journal Articles

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Roberta Santos Azevedo, Hagop M. Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Samuel Urrutia, Carlos E. Bueso-Ramos, Keyur P. Patel, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Koji Sasaki

Blood (2024) 144 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2024-201864

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Guillermo Garcia-Manero, Yazan F Madanat, Mikkael A. Sekeres, Hetty E. Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary J. Schiller, Lucy Yan, Toufigh Gordi, Lisa Rojkjaer, Lewis R. Silverman

Blood (2024) 144 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2024-206096

Published: 2024

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Mehmet Sevki Uyanik, Guillermo Garcia-Manero, Abhishek Maiti, Farhad Ravandi, Kelly S. Chien, Danielle Hammond, Alexandre Bazinet, Heather Schneider, Stephany Hendrickson, Sherry Pierce, Hagop M. Kantarjian, Naveen Pemmaraju, Guillermo Montalban-Bravo

Blood (2024) 144 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2024-207503

Published: 2024

Journal Articles

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Yazan F Madanat, Amir T. Fathi, Guillermo Garcia-Manero, Gail J. Roboz, Justin M. Watts, Gabrielle T. Prince, Praneeth Baratam, Stephane De Botton, Anthony S. Stein, James M. Foran, Martha L. Arellano, David Sallman, Yuanye (Vickie) Zhang, Stephanie M. Kapsalis, Prapti A. Patel, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2024-204862

Published: 2024

Journal Articles

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

Blood (2024) 144 (Supplement 1): 4981.

https://doi.org/10.1182/blood-2024-209541

Published: 2024

Journal Articles

Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2024-206248

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Maroof Hasan, Shahid Tannu, Shikha Saini, Manuel Ugidos, Guillermo Garcia-Manero, Uwe Platzbecker, Ching-Pin Chang, Anita K. Gandhi, Ricardo Garcia, Rajasekhar N.V.S. Suragani

Blood (2024) 144 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2024-194241

Published: 2024

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)

Marie Sebert, Uwe Platzbecker, David Valcarcel Ferreiras, Valeria Santini, Uma Borate, Stephanie M. Kapsalis, Lorene Simonot, Weishi Yuan, Prapti A. Patel, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 1845.1.

https://doi.org/10.1182/blood-2024-198172

Published: 2024

Journal Articles

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Juan Jose Rodriguez Sevilla, Yang Liu, Irene Ganan-Gomez, Vera Adema, Kelly S. Chien, Guillermo Montalban-Bravo, Natthakan Thongon, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna, Sanam Loghavi, Hui Yang, Linghua Wang, Simona Colla

Blood (2024) 144 (Supplement 1): 50.

https://doi.org/10.1182/blood-2024-202641

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only